Companies
Lilly (Eli)
S&P 500Health Care· USA

LLY

Disruptor

Lilly (Eli)

DIS

$929.55

-1.04%

Open $939.97·Prev $939.33

as of 13 Apr

DISRUPTOR

Power Core

Lilly's moat is the intersection of best-in-class GLP-1 efficacy data and a manufacturing capacity wall that competitors cannot scale in parallel.

Published1 Apr 2026
UniverseS&P 500
SectorHealth Care

Direction of Movement

Upward on Multiple Converging Growth Vectors

ROC 200

+15.8%

Referenced in 5 other analyses

Company Profile

Eli Lilly and Company is a leading pharmaceutical company engaged in the discovery, development, manufacture, and sale of human pharmaceutical products. It focuses on innovative medicines addressing critical health needs in areas such as diabetes, oncology, immunology, neuroscience, obesity, cardiovascular diseases, cancer, and other therapeutic categories including bone muscle joint disorders, endocrine conditions, dermatology, autoimmune diseases, sleep apnea, migraine, and Alzheimer's disease. The company offers treatments like insulins, GLP-1 therapies for diabetes and obesity, oncology drugs, immunologic agents, and neuroscience products. Eli Lilly and Company supports access initiatives through partnerships for technology transfer and API supply to manufacturers in low- and middle-income countries, enhancing availability of insulins and other therapies in regions like Africa and Bangladesh. It maintains a robust research and development pipeline targeting non-communicable diseases, with late-stage projects in diabetes, cardiovascular, and oncology areas. Founded in 1876 and headquartered in Indianapolis, Indiana, Eli Lilly and Company plays a significant role in the global health technology sector by delivering therapies that improve patient outcomes across diverse medical fields.

Sector

Healthcare

Industry

Drug Manufacturers - General

Employees

50,000

This page is for informational purposes only and does not constitute investment advice. L17X Research is an independent research service.